Predict your next investment

HEALTHCARE | Medical Devices & Equipment / Surgical Devices
nellix.com

See what CB Insights has to offer

Stage

Acquired | Acquired

Total Raised

$16.5M

Valuation

$0000 

About Nellix Endovascular

Nellix has developed a percutaneously deliverable endograft for the treatment of Abdominal Aortic Aneurysms and Thoracic Aortic Aneurysms. This aortic endograft device and treatment fills the aneurysm, providing a highly stable and durable seal. The technology aims to allow treatment of all aortic aneurysms and aims to provide a distinct advantage over current therapies.

Nellix Endovascular Headquarter Location

2465-B Faber Place

Palo Alto, California, 94303,

United States

650-213-8700

Latest Nellix Endovascular News

Endologix announces completion of enrollment in the EVAS2 Confirmatory Clinical Study to evaluate the Nellix EndoVascular Aneurysm Sealing System

May 12, 2020

News Endologix announces completion of enrollment in the EVAS2 Confirmatory Clinical Study to evaluate the Nellix EndoVascular Aneurysm Sealing System The Company is currently in the process of preparing a PMA submission, which it plans to submit shortly after the first 95 patients in the trial reach one-year follow-up in March 2021 Endologix completes enrolling patients for EVAS2 Confirmatory Clinical Study. Endologix, a developer and marketer of innovative treatments for aortic disorders, today announced that it has completed enrollment in the EVAS2 Confirmatory Clinical Study to Evaluate the Nellix EndoVascular Aneurysm Sealing (EVAS) System. “The completion of enrollment in our EVAS2 study is an exciting milestone for Endologix and for the treatment of abdominal aortic aneurysms,” commented John Onopchenko, Chief Executive Officer of Endologix. “We are very grateful for the ongoing collaboration and partnership with our investigators who continue to work side-by-side with us to make this trial successful.” In response to the current COVID-19 pandemic and the delay in recruiting patients across many clinical trials, Endologix submitted an IDE supplement to the FDA with a revised Statistical Analysis Plan that is consistent with the recently published FDA Guidance document, Conduct of Clinical Trials of Medical Products during COVID-19 Pandemic. The submission proposed a minimum sample size of 95 patients, with no alteration to the defined end points of the study. The power of the two-year effectiveness endpoint has been reduced to 87.4% from 93.8%, and the power of the safety endpoint remains 99.9%. The statistical power of both end points remains well above the 80% benchmark typically used in this therapeutic area. The Company is currently in the process of preparing a PMA submission, which it plans to submit shortly after the first 95 patients in the trial reach one-year follow-up in March 2021. Source: Company Press Release

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Nellix Endovascular Patents

Nellix Endovascular has filed 21 patents.

The 3 most popular patent topics include:

  • Vascular diseases
  • Vascular surgery
  • Diseases of the aorta
patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/13/2018

2/2/2021

Vascular diseases, Diseases of the aorta, Implants (medicine), Vascular surgery, Cardiac surgery

Grant

Application Date

7/13/2018

Grant Date

2/2/2021

Title

Related Topics

Vascular diseases, Diseases of the aorta, Implants (medicine), Vascular surgery, Cardiac surgery

Status

Grant

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.